Rilpivirine (Edurant) for the indication ‘infection with HIV-1’

For the treatment of adult, therapy-naive patients infected with HIV-1 and with a virus concentration ≤ 100,000 copies/mL, the therapeutic value of the combination rilpivirineemtricitabine- tenofovir is comparable with that of the combination efavirenz-emtricitabinetenofovir.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.